# Sulforadex in Healthy Human Males MAD

> **NCT02055716** · PHASE1 · COMPLETED · sponsor: **Evgen Pharma** · enrollment: 18 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Sulforadex
- **DRUG:** alpha-cyclodextrin

## Key facts

- **NCT ID:** NCT02055716
- **Lead sponsor:** Evgen Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055716, "Sulforadex in Healthy Human Males MAD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02055716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*